This study evaluated 82 patients treated with IMRT (52.2%) and 56 patients treated with IMPT (53.3%). Patients were asked to complete the questionnaire at baseline and 24 months post-RT. Patient-reported data in bowel function (BF), urinary irritative and/or obstructive symptoms (UO), and urinary incontinence (UI) domains of EPIC-26 was analyzed. A higher proportion of patients treated with IMRT had a clinically relevant reduction in BF when compared with IMPT (47.37% vs. 25.93%, p = 0.017) at 2-year. The mean changes in the UI and UO scores of the IMRT and IMPT cohorts were neither statically significant nor clinically relevant.